Vericel
NASDAQ · VCEL·Cambridge, MA·Small-cap·Approved
Commercial-stage specialty biologics company focused on advanced therapies for sports medicine and severe burn care. MACI is the only FDA-approved autologous cell therapy for cartilage repair in the knee; Epicel is a permanent skin replacement for adult and pediatric severe burns; NexoBrid is an enzymatic eschar removal product for severe thermal burns.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Vericel Corporate Presentation — March 2026 | Corporate overview | March 15, 2026 | 23 |